{"id":112,"date":"2013-02-04T17:06:51","date_gmt":"2013-02-04T22:06:51","guid":{"rendered":"http:\/\/licensinglaw.net\/blog3\/?page_id=112"},"modified":"2021-04-12T10:43:50","modified_gmt":"2021-04-12T14:43:50","slug":"inter-partes","status":"publish","type":"page","link":"https:\/\/licensinglaw.net\/blog3\/?page_id=112","title":{"rendered":"Inter partes"},"content":{"rendered":"<p style=\"text-align: justify;\">The new law makes <em>inter partes<\/em> post-grant proceedings easier to file and perhaps easier to win.\u00a0 Well before the new law, however, we were successfully prosecuting <em>inter partes<\/em> proceedings.<\/p>\n<p style=\"text-align: justify;\">For example, over a decade ago, the world&#8217;s largest manufacturer of diabetes drugs wanted freedom to operate for a new dosage form.\u00a0\u00a0 A patent with several potentially problematic claims stood in the way.\u00a0 Obtaining personal jurisdiction\u00a0for a <em>Declaratory Judgment<\/em> action\u00a0was complicated by the\u00a0fact that the legal title of the patent was owned by a State government.\u00a0 \u00a0We thus used an <em>inter partes<\/em> proceeding to contest the problematic legal claims.<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Enteric_tabletZoomed.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-861 size-thumbnail\" src=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Enteric_tabletZoomed-150x150.jpg\" alt=\"\" width=\"150\" height=\"150\" srcset=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Enteric_tabletZoomed-150x150.jpg 150w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Enteric_tabletZoomed-432x432.jpg 432w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Enteric_tabletZoomed-268x268.jpg 268w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/a>The case came out better than we&#8217;d even asked for:\u00a0\u00a0 the Patent<a href=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Inter_partes_reexaminationZoomed.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-860 size-thumbnail\" src=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Inter_partes_reexaminationZoomed-150x150.jpg\" alt=\"\" width=\"150\" height=\"150\" srcset=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Inter_partes_reexaminationZoomed-150x150.jpg 150w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Inter_partes_reexaminationZoomed-432x432.jpg 432w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/Inter_partes_reexaminationZoomed-268x268.jpg 268w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/a> Office found invalid each of the problematic legal claims, and all the other legal claims as well.\u00a0 Underscoring the quality of the <em>Request<\/em>, the Patent Office maintained its rejections through half a dozen attempts to reverse them.<\/p>\n<p style=\"text-align: justify;\">Our long experience in <em>inter partes<\/em> proceedings enables us to precisely calculate the investment required for this type of proceeding, from preparing the initial filing to arguing a Federal Circuit appeal.\u00a0 To find out the investment required for your case, <a href=\"https:\/\/licensinglaw.net\/blog3\/?page_id=22\"><em>contact us<\/em><\/a>.<\/p>\n<p style=\"text-align: justify;\"><a href=\"http:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/Enteric_tablet.jpg\">\u00a0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The new law makes inter partes post-grant proceedings easier to file and perhaps easier to win.\u00a0 Well before the new law, however, we were successfully prosecuting inter partes proceedings. For example, over a decade ago, the world&#8217;s largest manufacturer of diabetes drugs wanted freedom to operate for a new dosage &#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":19,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"template-full-width.php","meta":{"footnotes":""},"class_list":["post-112","page","type-page","status-publish","hentry","column","twocol"],"_links":{"self":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=112"}],"version-history":[{"count":15,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/112\/revisions"}],"predecessor-version":[{"id":862,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/112\/revisions\/862"}],"up":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/19"}],"wp:attachment":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}